Peringatan Keamanan

Farydak carries a Boxed Warning alerting patients and health care professionals that severe diarrhea and severe and fatal cardiac events, arrhythmias and electrocardiogram (ECG) changes have occurred in patients receiving Farydak. Because of these risks, Farydak is being approved with a Risk Evaluation and Mitigation Strategy (REMS) consisting of a communication plan to inform health care professionals of these risks and how to minimize them.

Panobinostat

DB06603

small molecule approved investigational

Deskripsi

Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.

Struktur Molekul 2D

Berat 349.434
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 30 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

After a 20 mg dose, panobinostat was quickly absorbed with a time to maximum absorption of 2 hours.

Metabolisme

Panobinostat was extensively metabolized to 77 metabolites. Unchanged panobinostat recovered in urine and feces was 2% and 3%, respectively. Primary metabolic pathways of panobinostat are reduction, hydrolysis, oxidation, and glucuronidation processes. CYP and non-CYP enzymes were found to play significant role in metabolism, CYP2D6 and CYP2C19 playing minor roles.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

5 Data
  • 1. Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of panobinostat.
  • 2. Exercise caution with St. John's Wort. This herb induces CYP3A4 metabolism, which may reduce the serum concentration of panobinostat.
  • 3. Take at the same time every day.
  • 4. Take with a full glass of water.
  • 5. Take with or without food.

Interaksi Obat

1227 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Panobinostat.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Panobinostat.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Panobinostat.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Panobinostat.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Panobinostat.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Panobinostat.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Panobinostat.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Panobinostat.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Panobinostat.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Panobinostat.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Panobinostat.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Panobinostat.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Panobinostat.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Panobinostat.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Panobinostat.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Panobinostat.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Panobinostat.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Panobinostat.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Panobinostat.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Panobinostat.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Panobinostat.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Panobinostat.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Panobinostat.
Cladribine Panobinostat may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Panobinostat.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Panobinostat.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Panobinostat.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Panobinostat.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Panobinostat.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Panobinostat.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Panobinostat.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Panobinostat.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Panobinostat.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Panobinostat.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Panobinostat.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Panobinostat.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Panobinostat.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Panobinostat.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Panobinostat.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Panobinostat.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Panobinostat.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Panobinostat.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Panobinostat.
Oxaliplatin The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Panobinostat.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Panobinostat.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Panobinostat.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Panobinostat.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Panobinostat.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Panobinostat.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Panobinostat.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Panobinostat.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Panobinostat.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Panobinostat.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Panobinostat.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Panobinostat.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Panobinostat.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Panobinostat.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Panobinostat.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Panobinostat.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Panobinostat.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Panobinostat.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Panobinostat.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Panobinostat.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Panobinostat.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Panobinostat.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Panobinostat.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Panobinostat.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Panobinostat.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Panobinostat.
Thalidomide The metabolism of Panobinostat can be increased when combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Panobinostat.
Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Panobinostat.
Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Panobinostat.
Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Panobinostat.
Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Panobinostat.
Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Panobinostat.
Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Panobinostat.
Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Panobinostat.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Panobinostat.
Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Panobinostat.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Panobinostat.
Stepronin The risk or severity of adverse effects can be increased when Stepronin is combined with Panobinostat.
Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Panobinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Panobinostat.
Brequinar The risk or severity of adverse effects can be increased when Brequinar is combined with Panobinostat.
Thiotepa The risk or severity of adverse effects can be increased when Thiotepa is combined with Panobinostat.
Aldosterone The risk or severity of adverse effects can be increased when Aldosterone is combined with Panobinostat.
Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Panobinostat.
Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Panobinostat.
Interferon alfa The risk or severity of adverse effects can be increased when Interferon alfa is combined with Panobinostat.
Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Panobinostat.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Panobinostat.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Human interferon omega-1 is combined with Panobinostat.
Mepolizumab The risk or severity of adverse effects can be increased when Panobinostat is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Panobinostat is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Panobinostat is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Panobinostat is combined with Bendamustine.
Cabazitaxel The risk or severity of adverse effects can be increased when Panobinostat is combined with Cabazitaxel.
Pralatrexate The risk or severity of adverse effects can be increased when Panobinostat is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Panobinostat is combined with Wortmannin.

Target Protein

Histone deacetylase 1 HDAC1
Histone deacetylase HDAC1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 16428510
    Qian DZ, Kato Y, Shabbeer S, Wei Y, Verheul HM, Salumbides B, Sanni T, Atadja P, Pili R: Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589. Clin Cancer Res. 2006 Jan 15;12(2):634-42.
  • PMID: 26362997
    Laubach JP, Moreau P, San-Miguel JF, Richardson PG: Panobinostat for the Treatment of Multiple Myeloma. Clin Cancer Res. 2015 Nov 1;21(21):4767-73. doi: 10.1158/1078-0432.CCR-15-0530. Epub 2015 Sep 11.

Contoh Produk & Brand

Produk: 15 • International brands: 2
Produk
  • Farydak
    Capsule • 10 mg • Oral • EU • Approved
  • Farydak
    Capsule • 10 mg • Oral • EU • Approved
  • Farydak
    Capsule • 10 mg • Oral • EU • Approved
  • Farydak
    Capsule • 15 mg • Oral • EU • Approved
  • Farydak
    Capsule • 15 mg • Oral • EU • Approved
  • Farydak
    Capsule • 15 mg • Oral • EU • Approved
  • Farydak
    Capsule • 20 mg • Oral • EU • Approved
  • Farydak
    Capsule • 20 mg • Oral • EU • Approved
Menampilkan 8 dari 15 produk.
International Brands
  • Faridak
  • Farydak

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul